At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 425 enrolled
Drug / intervention
MT10109L +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Lateral Canthal Lines With or Without Concurrent Treatment of Glabellar Lines
In Brief
A Phase 3 clinical trial evaluating MT10109L and Placebo for Lateral Canthal Lines and Glabellar Lines. Completed, enrolled 425 participants across 20 sites in 3 countries.
Detailed Summary
To evaluate the safety and efficacy of MT10109L for the treatment of lateral canthal lines (LCL) with or without concurrent treatment of glabellar lines (GL) in participants with moderate to severe LCL and GL.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLateral Canthal Lines, Glabellar Lines
CountriesCanada, Germany, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
Enrollment StartNov 2018
First PostedNov 2018
Primary CompletionMar 2020
Study CompletionJan 2021
TodayJul 2026
First PostedNov 7, 2018
Enrollment StartNov 5, 2018
Primary CompletionMar 5, 2020
Study CompletionJan 25, 2021
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 7.7 years ago
Interventions
MT10109Ldrug
MT10109L will be injected into either the LCL, or both the LCL and GL.
Placebodrug
Placebo will be injected into either the GL, or both the LCL and GL.